Literature DB >> 22128163

ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.

Gouriprassana Roy1, Ekaterina Placzek, Thomas S Scanlan.   

Abstract

3-Iodothyronamine (T(1)AM) is a biogenic amine derivative of thyroid hormone present in tissue and blood of vertebrates. Approximately 99% of the circulating thyroid hormones are bound to plasma proteins, including three major thyroid hormone-binding proteins, and the question arises as to whether circulating T(1)AM is also bound to serum factors. We report here that T(1)AM is largely bound to a single protein component of human serum. Using T(1)AM-affinity chromatography, we isolated this protein, and sequence analysis identified it as apolipoprotein B-100 (apoB-100), the protein component of several low density lipoprotein particles. Consistent with this finding, we demonstrate that >90% of specifically bound T(1)AM in human serum resides in the apoB-100-containing low density lipoprotein fraction. T(1)AM reversibly binds to apoB-100-containing lipoprotein particles with an equilibrium dissociation constant (K(D)) of 17 nm and a T(1)AM/apoB-100 stoichiometry of 1:1. Competition binding assays demonstrate that this binding site is highly selective for T(1)AM. Intracellular T(1)AM uptake is significantly enhanced by apoB-100-containing lipoprotein particles. Modest enhancements to apoB-100 cellular uptake and secretion by T(1)AM were observed; however, multidose T(1)AM treatment did not affect lipid or lipoprotein inventory in vivo. Thus, it appears that apoB-100 serves as a carrier of circulating T(1)AM and affords a novel mechanism by which T(1)AM gains entry to cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128163      PMCID: PMC3265861          DOI: 10.1074/jbc.M111.275552

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Lipoprotein-X stimulates monocyte chemoattractant protein-1 expression in mesangial cells via nuclear factor-kappa B.

Authors:  E G Lynn; Y L Siow; J Frohlich; G T Cheung; K O
Journal:  Kidney Int       Date:  2001-08       Impact factor: 10.612

Review 2.  Thyroxine-binding proteins.

Authors:  J Robbins
Journal:  Prog Clin Biol Res       Date:  1976

3.  Receptor-mediated endocytosis of low-density lipoprotein in cultured cells.

Authors:  J L Goldstein; S K Basu; M S Brown
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion.

Authors:  Jean B Regard; Hiroshi Kataoka; David A Cano; Eric Camerer; Liya Yin; Yao-Wu Zheng; Thomas S Scanlan; Matthias Hebrok; Shaun R Coughlin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Binding of thyroid hormones to human plasma lipoproteins.

Authors:  S Benvenga; R E Gregg; J Robbins
Journal:  J Clin Endocrinol Metab       Date:  1988-07       Impact factor: 5.958

6.  3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone.

Authors:  Thomas S Scanlan; Katherine L Suchland; Matthew E Hart; Grazia Chiellini; Yong Huang; Paul J Kruzich; Sabina Frascarelli; Dane A Crossley; James R Bunzow; Simonetta Ronca-Testoni; Emil T Lin; Daniel Hatton; Riccardo Zucchi; David K Grandy
Journal:  Nat Med       Date:  2004-05-16       Impact factor: 53.440

7.  Modification of low density lipoprotein by lipoprotein lipase or hepatic lipase induces enhanced uptake and cholesterol accumulation in cells.

Authors:  M Aviram; E L Bierman; A Chait
Journal:  J Biol Chem       Date:  1988-10-25       Impact factor: 5.157

8.  Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr.

Authors:  Marcus Ståhlman; Pia Davidsson; Ida Kanmert; Birgitta Rosengren; Jan Borén; Björn Fagerberg; Germán Camejo
Journal:  J Lipid Res       Date:  2007-11-18       Impact factor: 5.922

9.  Cruciferous indole-3-carbinol inhibits apolipoprotein B secretion in HepG2 cells.

Authors:  Geoffrey K Maiyoh; Joan E Kuh; Adele Casaschi; Andre G Theriault
Journal:  J Nutr       Date:  2007-10       Impact factor: 4.798

10.  The peroxisome proliferator-activated receptor alpha (PPARalpha) agonist ciprofibrate inhibits apolipoprotein B mRNA editing in low density lipoprotein receptor-deficient mice: effects on plasma lipoproteins and the development of atherosclerotic lesions.

Authors:  Tao Fu; Debnath Mukhopadhyay; Nicholas O Davidson; Jayme Borensztajn
Journal:  J Biol Chem       Date:  2004-04-27       Impact factor: 5.157

View more
  10 in total

1.  Evolutionary Conservation of 3-Iodothyronamine as an Agonist at the Trace Amine-Associated Receptor 1.

Authors:  Maxi Cöster; Heike Biebermann; Torsten Schöneberg; Claudia Stäubert
Journal:  Eur Thyroid J       Date:  2015-05-29

2.  Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4.

Authors:  Sarah A Hackenmueller; Maja Marchini; Alessandro Saba; Riccardo Zucchi; Thomas S Scanlan
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

Review 3.  Thyroid hormone regulation of metabolism.

Authors:  Rashmi Mullur; Yan-Yun Liu; Gregory A Brent
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

4.  Metformin inhibition of colorectal cancer cell migration is associated with rebuilt adherens junctions and FAK downregulation.

Authors:  Gastón Amable; Eduardo Martínez-León; María Elisa Picco; Sergio I Nemirovsky; Enrique Rozengurt; Osvaldo Rey
Journal:  J Cell Physiol       Date:  2020-04-02       Impact factor: 6.384

Review 5.  Update on 3-iodothyronamine and its neurological and metabolic actions.

Authors:  Riccardo Zucchi; Alice Accorroni; Grazia Chiellini
Journal:  Front Physiol       Date:  2014-10-16       Impact factor: 4.566

Review 6.  Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?

Authors:  Hartmut H Glossmann; Oliver M D Lutz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-31       Impact factor: 5.555

Review 7.  Central Effects of 3-Iodothyronamine Reveal a Novel Role for Mitochondrial Monoamine Oxidases.

Authors:  Annunziatina Laurino; Elisa Landucci; Laura Raimondi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-06       Impact factor: 5.555

8.  Lipolytic Effects of 3-Iodothyronamine (T1AM) and a Novel Thyronamine-Like Analog SG-2 through the AMPK Pathway.

Authors:  Michael Rogowski; Lorenza Bellusci; Martina Sabatini; Simona Rapposelli; Shaikh M Rahman; Grazia Chiellini; Fariba M Assadi-Porter
Journal:  Int J Mol Sci       Date:  2019-08-20       Impact factor: 5.923

9.  Changes in Thyroid Metabolites after Liothyronine Administration: A Secondary Analysis of Two Clinical Trials That Incorporated Pharmacokinetic Data.

Authors:  Nour Diab; Sameer Desale; Mark Danielsen; Josef Köhrle; Nawar Shara; Jacqueline Jonklaas
Journal:  Metabolites       Date:  2022-05-24

Review 10.  3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?

Authors:  Grazia Rutigliano; Lavinia Bandini; Simona Sestito; Grazia Chiellini
Journal:  Int J Mol Sci       Date:  2020-03-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.